Pricing
  1. JP-listed companies
  2. RIBOMIC Inc.
  3. Financials
  4. Cash and cash equivalents

RIBOMIC Inc.【JP:4591】

Market cap
¥4.4B
P/E ratio
-3.8x
Ribomics develops next-generation aptamer drugs using its proprietary RiboART System to treat unmet medical needs like achondroplasia and eye diseases.
SummaryFinancialsDividendsHistoryOwnershipWorkforce
Period EndCash and cash equivalents (Million JPY)YoY (%)
Mar 31, 20251,837-12.51%
Mar 31, 20242,100-25.68%
Mar 31, 20232,825-2.64%
Mar 31, 20222,902-13.07%
Mar 31, 20213,338+108.40%
Mar 31, 20201,602+13.28%
Mar 31, 20191,414-10.56%
Mar 31, 20181,581-11.37%
Mar 31, 20171,784-4.12%
Mar 31, 20161,860-44.26%
Mar 31, 20153,337

Income Statement

RevenueRevenue growth (%)Cost of revenueGross profitGross margin (%)Research & developmentSelling, general & administrativeOperating margin (%)Operating expenses Operating income Income before tax Pretax margin (%)Provision for income taxesEffective tax rate (%)Net income Net income margin (%)Earnings per shareDiluted EPSDividend payout ratio (%)Dividend per shareEBITDAEBITDA margin (%)

Balance Sheet

Cash and cash equivalents Marketable securities, current Total cash & short-term investmentsAccounts receivable, netInventoriesTotal current assetsProperty, plant and equipment, netMarketable securities, non-current Total non-current assetsTotal assets Accounts payableShort-term debtLong-term debt, current Total current liabilitiesLong-term debt, non-current Total non-current liabilitiesTotal liabilities Common stock and paid-in capital Retained earningsStockholders' equityTotal debtNet debtD/E ratio (%)Working capital

Cash Flow

Depreciation & amortizationStock-based compensationCash from operations Capital expendituresCash from investing Payments for dividends Repurchases of common stockProceeds from issuance of term debt, netRepayments of term debtCash from financing Free cash flowFCF margin (%)